Lantern Pharma (LTRN) Gains from Investment Securities (2025)
Lantern Pharma's (LTRN) quarterly Gains from Investment Securities came in at $49988.0 in Q4 2025, down 31.22% on a QoQ basis from $72677.0 in Q3 2025.
Lantern Pharma (LTRN) Gains from Investment Securities (2025) Analysis & Trends
Lantern Pharma (LTRN) has 1 years of Gains from Investment Securities data on file, last reported at $49988.0 in Q4 2025.
- Quarterly Gains from Investment Securities changed N/A year-over-year to $49988.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $264913.0 (changed N/A YoY) and the FY2025 annual result came in at $264913.0, changed N/A from the prior year.
- Gains from Investment Securities declined to $49988.0 in Q4 2025, from $72677.0 in the prior quarter.
- In the past five years, Gains from Investment Securities ranged from a high of $142248.0 in Q1 2025 to a low of $49988.0 in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Lantern Pharma | 26.05 Mn | 26.05 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 49,988.00 |
| Dec 31, 2025 | 49,988.00 |
| Sep 30, 2025 | 72,677.00 |
| Sep 30, 2025 | 72,677.00 |
| Mar 31, 2025 | 142,248.00 |
| Mar 31, 2025 | 142,248.00 |